XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC.

@article{Zhang2010XL184AM,
  title={XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC.},
  author={Ying Zhang and Fadila Guessous and Alex Kofman and David Schiff and Roger Abounader},
  journal={IDrugs : the investigational drugs journal},
  year={2010},
  volume={13 2},
  pages={
          112-21
        }
}
XL-184 (BMS-907351), under development by Exelixis Inc and Bristol-Myers Squibb Co, is a pan-tyrosine kinase inhibitor for the potential oral treatment of medullary thyroid cancer, glioblastoma multiforme and NSCLC. The prinicipal targets of XL-184 are MET, VEGFR-2 and RET, but the drug is also reported to display inhibitory activity against KIT, FLT3 and TEK. Preclinical studies demonstrated that XL-184 potently inhibited multiple receptor tyrosine kinases in various cancer cell lines and… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 49 CITATIONS

Similar Papers

Loading similar papers…